Visugromab,Nivolumab
BMS,Catal ym
['nivolumab', 'nivo', 'catalym']
mwbn news: catalym announces initial data from ongoing phase 2a trial evaluating gdf-15-targeting antibody visugromab in combination with nivolumab at asco 2023: munich (business wire) catalym today ... #biotech #news 
#LifeScience news, jobs events: #Illinois #Indiana #Iowa #Kansas #Michigan #Minnesota #Missouri #Ohio #Wisconsin. Part of @BiotechNetworks, We Connect #Biotech.